News Related to Kyowa Kirin Co., Ltd.

Related coverage linked through entity extraction aliases.

Kura Oncology's Ziftomenib Hits 96% CRc in Frontline AML, FIT-001 Data at 2026 Summit

Jul 20, 2026

Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.

Antibody Market Poised for Strong Growth Through 2033 Amid Therapeutic Demand

Feb 16, 2026

The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.